Icalcaprant
| Icalcaprant | |
|---|---|
| Icalcaprant.png | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Icalcaprant (also known by its developmental code name BMS-986020) is a drug that was under investigation for the treatment of various inflammatory conditions. It is a selective antagonist of the prostaglandin D2 receptor 2 (DP2), also known as the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). This receptor is involved in the inflammatory response and is a target for therapeutic intervention in diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Mechanism of Action[edit]
Icalcaprant functions by selectively blocking the DP2 receptor, which is a G-protein coupled receptor involved in the mediation of inflammatory responses. The DP2 receptor is activated by prostaglandin D2 (PGD2), a lipid compound that plays a significant role in the pathophysiology of allergic and inflammatory diseases. By inhibiting this receptor, Icalcaprant reduces the recruitment and activation of eosinophils, basophils, and T-helper 2 cells, which are key players in the inflammatory process.
Clinical Development[edit]
Icalcaprant was developed by Bristol-Myers Squibb and underwent clinical trials to evaluate its efficacy and safety in treating inflammatory conditions. The drug showed promise in early-phase trials, particularly for its potential use in treating asthma and COPD. However, further development was discontinued due to strategic reasons and the competitive landscape of the pharmaceutical market.
Pharmacokinetics[edit]
The pharmacokinetic profile of Icalcaprant includes its absorption, distribution, metabolism, and excretion characteristics. It is administered orally and has been shown to have a favorable absorption profile. The drug is metabolized primarily in the liver, and its metabolites are excreted via the renal and fecal routes. The half-life of Icalcaprant allows for once-daily dosing, which is advantageous for patient compliance.
Potential Applications[edit]
Although the development of Icalcaprant was halted, the mechanism of DP2 antagonism remains a viable target for other therapeutic agents. The inhibition of the DP2 receptor could potentially benefit patients with a variety of inflammatory and allergic conditions, including allergic rhinitis, atopic dermatitis, and eosinophilic esophagitis.
